Hangzhou Tigermed Consulting Co Ltd ADR Logo
US41044T1088
HNGZY

Hangzhou Tigermed Consulting Co Ltd ADR

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Hangzhou Tigermed Consulting expects weaker EPS for quarter ended 30 June 2026

    Hangzhou Tigermed Consulting is expected to publish quarterly results for the period ended 30 June 2026 on 29 August 2026. Three analysts estimate average EPS of 0.185 CNY per share versus 0.260 CNY in the year-ago quarter. Two analysts expect revenue to increase 12.09 percent to 1.89 billion CNY (prior year: 1.69 billion CNY). For the current fiscal year, analysts’ estimates average 1.02 CNY EPS and 7.75 billion CNY revenue versus 1.04 CNY and 6.81 billion CNY in the prior year. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Hangzhou Tigermed Consulting Co Ltd ADR has already paid €0.0159 in dividends. The last payout was in August.

Financials

In the last quarter, Hangzhou Tigermed Consulting Co Ltd ADR had revenue of €274.41m and net profit of €18.58m
(EUR) September 2026
YoY
Revenue 274.41m 29.82%
Gross profit 74.19m 27.78%
Net profit 18.58m 75.50%
EBITDA 94.51m 0.10%

Fundamentals

Metric Value
Market capitalization
€6.22bn
Number of shares
1.54bn
52-week high/low
€4.04 - €3.63
Dividend yield
0.13%
Dividends TTM
€0.0159
Beta
0.41
P/E ratio
-99.75
PEG ratio
0.59
P/B ratio
2.03
P/S ratio
4.61

Company profile

Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

Name
Hangzhou Tigermed Consulting Co Ltd ADR
CEO
Xiao Chun Cao
Headquarters Hangzhou, tj
China
Website
IPO
11/07/2022
Employees 11,130

Ticker symbols

Exchange Symbol
Pnk
HNGZY
🍪

Parqet  uses cookies. Learn more